Mammalian soluble epoxide hydrolase (sEH) represents a highly promising new target for drug development. Chemical inhibition of this enzyme in animal models was shown to treat hypertension and vascular inXammation as well as related syndromes. Existing sEH inhibitors are relatively potent and speciWc. However, the low solubility and relatively fast metabolism of described sEH inhibitors make them less than therapeutically eYcient, stating the need for novel inhibitor structures. Therefore, a series of -cyanoester and -cyanocarbonate epoxides were evaluated as potential human sEH (HsEH) substrates for the high-throughput screen (HTS) of compound libraries. (3-Phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester (PHOME), which displayed the highest aqueous stability and solubility, was selected for the development of an HTS assay with long incubation times at room temperature. Concentrations of HsEH and PHOME were optimized to ensure assay sensitivity, reliability, and reproducibility. Assay validation, which employed these optimized concentrations, resulted in good accuracy (60-100%) and high precision (<7% relative standard deviation). In addition, an overall ZЈ value of 0.7 proved the system's robustness and potential for HTS. The developed assay system will be a valuable tool to discover new structures for the therapeutic inhibition of sEH to treat various cardiovascular diseases. © 2006 Elsevier Inc. All rights reserved.
matory actions [2] [3] [4] [5] . Recent results indicate the potential of this enzyme as a novel drug target by means of its chemical inhibition leading to the accumulation of EETs and other lipid epoxides in the organism. sEH inhibition experiments in rodent models have shown a successful treatment of hypertension [6] [7] [8] and inXammatory diseases [9, 10] as well as protection against renal damage caused by hypertension [8, 11] . Furthermore, sEH inhibition was suggested as potential therapy for ischemic stroke [12] .
Highly potent and selective inhibitors for sEH were developed in our laboratory [13] [14] [15] [16] [17] [18] and used to describe the biology associated with sEH [5, 19] . Although medicinal chemistry approaches were used to increase their inhibitory activity and solubility [16] [17] [18] , the latest compounds reported still do not possess physical properties to produce a successful pharmaceutical [20] . For example, the sEH inhibitor AUDA (12-[3-adamantane-1-yl-ureido]-dodecanoic acid) is only 30% orally available and thus can work only with careful formulation. This is due to less than optimal pharmacokinetic properties [21] . Thus, although sEH urea-based inhibitors are good in vitro and are valuable experimental tools, they should be improved toward higher biological availability and stability for possible future orally administered in vivo drugs. Therefore, there is a need for novel sEH inhibitor structures and optimized urea, amide, and carbamate inhibitors.
To select structures leading to potent sEH inhibitors, it is necessary to develop a robust and sensitive enzymatic screening tool. A 96-well plate spectrophotometric assay was used to develop the Wrst generation of sEH inhibitors; however, this assay was not sensitive enough to distinguish among the best compounds, and the instability of the corresponding substrate requires short incubation times [13, 15, 22] . In addition, several radiochemical and chromatographic assays were developed [23] . Unfortunately, they are too slow and labor intensive to screen large compound libraries. To obtain higher sensitivity and a rapid response, we recently reported a series of novel Xuorescent substrates and the development of a rapid kinetic Xuorescent assay for sEH inhibition [24] . The reaction mechanism of these initially nonXuorescent structures is based on the hydrolysis of their epoxide moiety by the enzyme, followed by an intramolecular cyclization, and resulting in the release of a cyanohydrin ( Fig. 1) . Under basic conditions, the cyanohydrin rapidly decomposes into a cyanide ion as well as the highly Xuorescent 6-methoxy-2-naphthaldehyde, which is characterized by a large Stoke's shift. This assay is approximately two orders of magnitude more sensitive than the previous spectrophotometric assay [24] . Although this later assay is very useful to measure inhibition potency quickly and sensitively, it does not allow the screen of a compound library in a high-throughput screen (HTS) manner because of the relatively low solubility and stability of the substrate. Therefore, we report here the development of a Xuorescent endpoint assay with long incubation times at room temperature conditions for human soluble epoxide hydrolase (HsEH).
Materials and methods

Enzymes and reagents
Recombinant HsEH was produced, puriWed, analyzed, and quantiWed as described previously [25, 26] . All chemicals and reagents were purchased from Sigma Chemical (St. Louis, MO, USA) unless otherwise indicated. Fluorescent substrates were synthesized as described by Jones and coworkers [24] . 6-Methoxy-2-naphthaldehyde was purchased from Avocado Research Chemicals (Heysham, UK). Inhibitors were made previously in the laboratory [13, 15] . For both substrates and inhibitors, 100£ solutions in dimethyl sulfoxide (DMSO) were prepared and kept at ¡20°C until used.
Determination of aqueous solubility, aqueous stability, and Michaelis-Menten parameters
Aqueous solubility and Michaelis-Menten parameters of all Xuorescent sEH substrates were determined and carried out as described previously [24] . In brief, aqueous solubility was determined by adding varying concentrations of substrate in DMSO to 25 mM BisTris-HCl buVer (pH 7.0) containing 0.1 mg/ml bovine serum albumin (BSA) in a Wnal ratio of 1:99 (v/v). Insolubility of the inhibitor was indicated by the increase in turbidity of the water solution. The turbidity was measured as absorbance at 800 nm on a SpectraMax 340PC 384 microplate reader (Molecular Devices, Sunnyvale, CA, USA) at 30°C. Experiments to determine MichaelisMenten parameters were carried out by testing a constant HsEH concentration with various Wnal substrate concentrations in 25 mM BisTris-HCl buVer (pH 7.0) containing 0.1 mg/ml BSA. Enzyme concentrations were 9.4, 2.8, 9.4, 2.8, 141.7, 2.8, 5.7, and 5.7 nM for substrates 2 through 9 (cf. Fig. 1 . Reaction mechanism of (3-phenyl-oxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester (PHOME) with sEH. This compound was selected as substrate for the long-term Xuorescent endpoint assay developed in the current study.
30°C. Linear regression analyses were performed to calculate initial velocities ( ). Lineweaver-Burk transformation of the resulting data was carried out. Subsequent linear regression analysis of seven data points supported the calculation of the desired Michaelis-Menten parameters. BuVer-catalyzed hydrolysis rates, and thus aqueous stabilities, were determined by means of a SpectraFluor Plus Xuorescent plate reader. This instrument monitored the appearance of 6-methoxy-2-naphthaldehyde for 10 min every 30 s employing the abovedescribed settings. For this purpose, 1-mM DMSO stock solutions of all compounds were diluted 1:99 (v/v) with 25 mM BisTris-HCl buVer (pH 7.0) containing 0.1 mg/ml BSA, and 200 l of the resulting mixtures was examined in 30 replicates. Subsequently, hydrolysis rates were calculated by linear regression analyses.
Endpoint assay optimization
Optimization of the endpoint assay was performed with techniques similar to those described for a kinetic assay employing sEH [24] . A checkerboard assay, which tested combinations of several Wnal concentrations of (3-phenyloxiranyl)-acetic acid cyano-(6-methoxy-naphthalen-2-yl)-methyl ester (PHOME, 15-50 M) and serial dilutions of HsEH (0-0.33 g/well) in 25 mM BisTris-HCl buVer (pH 7.0) containing 0.1 mg/ml BSA, was carried out. Enzyme and substrate concentrations, optimized for a signal/background ratio of 4-5 and the lowest possible protein concentrations to enhance assay sensitivity, were conWrmed in quadruplicate. Appearance of the reporter molecule 6-methoxy-2-naphthaldehyde was detected at room temperature for 2 h every 3 min with a SpectraMax M2 microplate reader (Molecular Devices) and the following instrumental settings: excitation wavelength, 316 nm; emission wavelength, 460 nm (cutoV, 455 nm); number of reads per well, 3. The excitation and emission maxima of 6-methoxy-2-naphthaldehyde were determined earlier by the same plate reader under assay conditions.
Inhibitor assays
Inhibitors were tested for their IC 50 values with the Xuorescent endpoint assay system and compared with similar Table 1 Ranges for apparent limit of solubility, autohydrolysis rates, and k cat /K m ratios of Xuorescent substrates for sEH in aqueous solution Note. Apparent limit of solubility (LS) was determined by photometric turbidity analysis at 800 nm. Autohydrolysis rates of 10-M substrate solutions are given as averages § standard deviations (n D 30). SpeciWcity constants k cat /K m values are provided as means § standard deviations (n D 3).
a Substrate numbers (#) correspond to those in Jones and coworkers [24] . 
Cl data generated by the method of Jones and coworkers [24] . Therefore, PHOME at a Wnal concentration of 50 M (Wnal DMSO content/well was 1%) and apparently homogeneous HsEH at 3 nM were employed under room temperature conditions. Prior to the addition of substrate, inhibitors were incubated with the enzyme for 10 min. Fluorescence measurements were obtained on a SpectraMax M2 microplate reader with the above-mentioned settings in two diVerent ways. For one set of experiments, single endpoint readings were taken after a 60-min reaction time in darkness (n 7 5); for the other set of experiments, Xuorescence monitoring was carried out for 60 min every 3 min (n D 3).
IC 50 values were determined by linear regression analyses employing at least three replicated data points at diVerent concentrations in the linear range of the resulting inhibition curve (between 20 and 80% enzyme activity reduction). In addition, assay validation for the endpoint assay system was performed. Therefore, inhibitors at single concentrations as well as their carrier DMSO were incubated individually for 10 min with HsEH as described above (n D 4). Final concentrations of inhibitors were 10 M CEU (1-cyclohexyl-3-ethyl urea), 0.1 M CHU (1-cyclohexyl-3-hexyl urea), 10 M DCU (1,3-dicyclohexyl urea), 0.1 M CDU (1-cyclohexyl-3-dodecyl urea), and 0.1 M AUDA. After the addition of substrate (Wnal concentration of PHOME, 50 M; total assay volume, 200 l), the black 96-well polystyrene assay plates (Greiner Bio-One, Longwood, FL, USA) were sealed and kept in the dark at room temperature. After 1 h, the Xuorescent signal was acquired once with a SpectraMax M2 plate reader employing the abovementioned settings. After further 30-min incubation, measurements were repeated. Assay evaluation was performed four times per day on 3 consecutive days to detect variations within a plate as well as from plate to plate and from day to day.
Evaluation of candidate stop solutions
Several chemicals were tested for their suitability as stop solution for the Xuorescent endpoint system employing HsEH. Thus, they were examined for their ability to prohibit enzyme-substrate interactions and substrate autohydrolysis as well as to maintain the existing Xuorescent signal.
Reactions were conducted using optimized assay conditions. After 1 h in darkness under room temperature conditions, 50 l of the potential stop solutions was added to the reactions as well as to 50 l of 25 mM BisTris-HCl buVer (pH 7.0) containing 0.1 mg/ml BSA as a control. Initially, 20 diVerent stop solutions were tested (for details, see Supplemental information). After the addition of candidate stop solutions, the Xuorescent signals of all reactions were monitored every minute for at least 10 min as described above. For the initial screen of stop solutions, reactions were carried out without replicates, whereas the later experiments that employed Zn(NO 3 ) 2 and ZnSO 4 solutions of various concentrations were conducted in triplicate. The resulting data were further analyzed relative to the respective reference-the variant where buVer was added instead of a candidate stop solution. Hydrolysis rates were determined by linear regression analyses employing the plate reader's software SoftMax Pro 4.7.
To evaluate the inXuence of Zn(NO 3 ) 2 and ZnSO 4 on stopping the PHOME assay, we Wrst tested the eVect of their Wnal concentrations (0.5-200 mM) on enzyme activity. During a second step, we evaluated the inXuence of the two zinc salts on the Xuorescent signal of 6-methoxy-2-naphthaldehyde. Calibration curves were obtained as described previously [24] in the absence or presence of 200 mM of Zn(NO 3 ) 2 or ZnSO 4 . Subsequently, 50 l of buVer, 1 M Zn(NO 3 ) 2 solution (dissolved in water), or 1 M ZnSO 4 solution (dissolved in water) was added to a set of standard solutions (Wnal assay volume of 250 l), resulting in data for three distinct standardization curves containing seven data points each. Single Xuorescence readings were taken again with a SpectraMax M2 microplate reader and using the corresponding detection setup. Subsequently, data were analyzed by linear regression analyses.
Results and discussion
High-throughput enzyme assays for screening large compound libraries are generally set up as endpoint tests with comparatively long reaction times [27] [28] [29] , in contrast to rapid kinetic assay systems such as the ones reported for IC 50 determinations of sEH inhibitors [22, 24, 30] . These conditions allow multiple 96-well, 384-well, or higher density well plates to be set up in parallel by hand or simple robotics. In addition, slight variations in incubation time or conditions will not signiWcantly alter the resulting screening data with on-plate calibrations. Due to the lack of such a method for sEH, we evaluated the recently developed Xuorescent substrates for sEH [24] with regard to this particular application.
Substrate characterization and selection
Candidate substrates were tested for aqueous solubility. The resulting turbidity data, which were determined via a change in absorbance at 800 nm, revealed that the aryl ester PHOME ( Fig. 1; compound 3 in Jones and coworkers [24] ) is the most soluble compound under the conditions employed (Table 1) . It represented the only structure in this series of compounds that was still soluble above a Wnal concentration of 50 M. This Wnding was surprising because carbonate compounds, like the majority of the tested substrates, are generally known to display better aqueous solubility than are esters. Bilinear regression analysis allowed the calculation of the apparent limit of solubility of PHOME. It was found to be 58 § 7 M (mean § SD, n D 3). In addition, the aqueous stability of this particular compound was the highest of all the compounds tested. It also had a hydrolysis rate that is approximately half of that for the substrate used for inhibition potency measurement [24] ( Table 1 ). Due to solubility limitations, we were generally only able to accurately obtain the speciWcity constant k cat / K m (Table 1) . For the combination PHOME/HsEH, the obtained value was 0.115 s ¡1 M
¡1
, which is in the middle of the range of the acquired values. In addition, k cat /K m ratios showed PHOME to be turned over roughly Wvefold slower than compound 7 [24] . Nevertheless, due to the higher solubility of PHOME and by employing the Lineweaver-Burk conversion, K m and V max values of this particular substrate could be acquired. They were found to be 272 M and 1.08 nmol min ¡1 , respectively. Altogether, these Wndings favored PHOME as substrate for a long-incubation endpoint assay for HsEH and thus for an HTS assay. Its comparatively high solubility and low autohydrolysis rate will allow a near steady-state reaction for more than 60 min of incubation time using comparatively low enzyme concentrations. This will decrease total cost and increase sensitivity for the screening of chemical libraries. In addition, the midrange k cat /K m value of the combination HsEH/PHOME ensures that the enzymatic reactions occur neither too slow nor too fast. The Wrst option could cause a too narrow separation band between maximum and minimum enzyme activities, whereas the second option could interfere with the relatively long reaction time and the steady-state condition of the reaction. However, both prospects should be avoided in this particular application.
Assay conditions and optimization
The assay optimization process was performed with the following conditions held constant: (i) the employed buVer was 25 mM BisTris-HCl (pH 7.0) containing 0.1 mg/ml BSA, (ii) the total assay volume was 200 l with a Wnal DMSO concentration of 1% (v/v) originating from the substrate stock solutions, (iii) the assay reaction time was 1 h as a compromise between enzyme activity decay (HsEH halflife is >8 h at 25°C in the assay conditions used [31] ) and sensitivity increase over time, and (iv) the experiments were conducted at room temperature (23 § 2°C) to simplify analysis.
Optimization of the substrate and enzyme concentration was done in a checkerboard experiment in which [PHOME] varied from 15 to 50 M and [HsEH] varied from 0 to 26 nM (Table 2 ). Optimized concentrations of HsEH and PHOME were found to be 3 nM and 50 M, respectively. These concentrations of enzyme and substrate ensured a linear substrate hydrolysis over a period of 1 h with minimal enzyme amount. Furthermore, a resulting signal/background ratio of at least 4 after 60 min still provided the desired assay sensitivity. Interestingly, the reporter molecule appearance maintained a linear correlation (r 2 D 0.994) after 90 min of incubation ( Fig. 2A ). After this time period, only approximately 30% of the total substrate amount was consumed. Therefore, endpoint readings of the developed inhibitor test can be taken anytime between 60 and 90 min after the reaction is started by the addition of substrate, still ensuring steady-state conditions and a constant substrate turnover rate.
The mechanism of the Xuorescent substrate decomposition basically occurs in three steps: epoxide hydrolysis, intramolecular cyclization, and conversion of the Table 2 Results of the checkerboard assay for the optimization of HsEH and PHOME concentrations Note. The three numbers given for each combination of concentrations represent, from top to bottom, (i) the squared linear correlation coeYcient (r 2 ) for 60 min of incubation time, (ii) the signal/background ratio after 60 min, and (iii) the percentage of substrate that was turned over after 60 min.
[PHOME] ( M)
[HsEH] (nM) cyanohydrin into 6-methoxy-2-naphthaledehyde (cf. Fig. 1 ). The optimized substrate and enzyme concentrations force the epoxide hydrolysis by HsEH to be the ratelimiting step of the reaction mechanism, and this is critical for the applicability of the assay. During the checkerboard assay, linear increase of the initial substrate turnover rate was demonstrated with an increasing protein amount up to 0.33 g/well at 50 M (Fig. 3) . This represents roughly 10 times more protein than that used in the optimized test system. Linear regression analysis of the corresponding data conWrmed the proportional relation with a correlation coeYcient of 0.999. If either the intramolecular cyclization or the cyanohydrin conversion step was the rate-limiting reaction, the increase in initial velocity increase would plateau at a certain protein concentration and thus not be linear anymore.
The optimized HsEH concentration of 3 nM is three times greater than that used in the rapid kinetic Xuorescent assay as reported by Jones and coworkers [24] suggesting less sensitivity. However, this reduction can be compensated for by a longer reaction time. The PHOME substrate concentration of 50 M is similar to that used in the previously described NEPC (4-nitrophenyl-trans-2,3-epoxy-3-phenylpropyl carbonate) colorimetric assay and the [ 3 H]tDPPO (trans-1,3-diphenylpropene oxide) radiochemical assay [23, 30] .
Assay validation
To validate the assay, we Wrst investigated its ability to diVerentiate between and classify known inhibitors of various potencies. IC 50 values of previously characterized sEH inhibitors were determined employing the endpoint assay system by continuously monitoring 6-methoxy-2-naphthaldehyde appearance (Fig. 2B) as well as by taking only single Xuorescent measurements after a reaction time of 1 h. In contrast to the kinetic Xuorescent assay for sEH [24] , which was used to test the same inhibitors, enzyme-inhibitor incubation was allowed to take place for 10 min (vs. 5 min) with regard to the future application of the assay. This time was selected to simplify the handling of multiple plates and to allow slow-binding inhibitors to fully inhibit the enzyme. Of course, this substrate also can be used for real-time assays.
IC 50 values obtained in a kinetic or endpoint mode with PHOME as substrate are similar for CHU, DCU, and AUDA but diVer for CEU and CDU (Table 3 ). The fourfold diVerence in the IC 50 values for CEU probably reXects the overall low sensitivity of the assay system for high IC 50 values. In contrast, we have no explanation for the twofold diVerence between the IC 50 values obtained for CDU. However, both modes of detection yield the same ranking of the investigated inhibitors. Therefore, the assay developed in this study could be employed either as an endpoint assay or as a kinetic test to rank inhibitors. The ranking of all tested inhibitors with the substrate PHOME was in accordance with the kinetic Xuorescent assay described by Jones and coworkers [24] . In addition, the obtained values were quite similar to those determined via the latter assay employing compound 7 ( Table 3 ), suggesting that the PHOME assay is as sensitive and eYcient as the previously described test system [24] to rank potent inhibitors. Furthermore, the assay using substrate 3 could distinguish between very potent inhibitors (CDU and AUDA) in accordance with the [ 3 H]tDPPO assay and in contrast to the NEPC test (Table 3) . Thus, the newly developed assay system is highly sensitive and covers a wide range of IC 50 values. However, the inhibitors CHU and DCU could not be diVerentiated statistically by their IC 50 values employing HsEH and PHOME, even though previous examinations were able to do so employing other test systems. The reason for this might be the prolonged enzyme-inhibitor incubation time, which was shown previously to result in divergent IC 50 values [30] . This is, of course, not signiWcant for a screening assay system and can be addressed, if necessary, by direct comparison of the compounds. Nevertheless, these experimental results conWrmed the suitability of the developed Xuorescent endpoint assay using PHOME for sEH inhibition tests.
In a second experiment, we determined the accuracy and precision of the endpoint assay with PHOME as substrate. Fluorescence was measured after 60 and 90 min of incubation at room temperature. To evaluate the coeYcient of variation (CV) of the assay and its accuracy, we measured the inhibition eVect of Wve inhibitors of various potencies at one concentration each in quadruplicate on every plate. The experiment was repeated four times per day on 3 consecutive days. Because the results after 60 and 90 min of incubation time were similar, Table 4 displays only the results of the longer incubation time. Intraplate relative standard deviations (or CVs) were found to be between 0.3 and 6.2%. The average CV of all acquired values was 2.4%. As shown in Table 4 , interplate variations ranged from 2 to 7% and over the 3 days variations were less than 6.5%.
Overall, the assay gives good accuracy on the Wrst day (>95%), but it slowly decreases over the next 2 days to reach only 60% for CEU on day 3. We generally observed less inhibition on the second day and even less on the [32] . In this case, values between 0.7 and 0.8 were found, demonstrating that the assay holds a large separation band between samples and blank signals and thereby conWrming its suitability for HTS. Except for DCU, whose inhibitory impact on the HsEH activity was extremely high (and thus the corresponding Xuorescent signal was too close to the blank signal), we obtained Z values [32] between 0.6 and 0.8. This means, that the assay has a separation band between 0 and 90% of inhibition in which it can diVerentiate inhibitors from each other. All of these Wndings establish the reliability and reproducibility of the developed Xuorescent endpoint HTS system for sEH inhibition.
Determination of a candidate stop solution
The search for an appropriate stop solution was carried out to increase Xexibility of the Xuorescent endpoint assay for HsEH. If it was possible to stop an ongoing substrate hydrolysis reaction and conserve the current signal, the endpoint assay could potentially be interrupted anytime between 60 and 90 min after the addition of substrate. Most important, the quantiWcation of the Xuorescent signal could be achieved independently from the assay starting time, and this would signiWcantly improve the adaptability of the system. A total of 20 chemicals and solutions were tested for their potential to function as stop solutions for the described Xuorescent endpoint assay system (see Supplementary material). Zn(NO 3 ) 2 and ZnSO 4 , which are known to inhibit the Cterminal epoxide hydrolase and N-terminal phosphatase activity of sEH [33, 34] , were able to signiWcantly inhibit the enzymatic reaction. We found that Wnal concentrations of at least 0.1 M of these two salts are necessary to stop the enzymatic reaction. In addition, a Wnal ZnSO 4 concentration of at least 0.2 M enhanced the Xuorescent signal of the reporter molecule by approximately 35%, whereas the same concentration of Zn(NO 3 ) 2 reduced it by 20% (see Supplemental information). However, the signal/noise ratio was not changed because both the sample and background Xuorescences were increased. If needed, high concentrations of ZnSO 4 can be used as stop solutions to inhibit the sEH activity with no decrease in Xuorescence intensity. Data in this study were generated without stop solutions to simplify the assay and because our plate design provided internal controls.
Further applications
In the current article, we have described the development of the Xuorescent HTS assay for a speciWc application: HTS of chemical libraries to Wnd new inhibitors for HsEH. Although this use is important, the technology could be extended to other applications. It could be used in combination with other epoxide hydrolases or other enzymes that hydrolyze epoxides to diols [35] . Furthermore, because the substrates contain an ester or carbonate function, esterases or lipases could also hydrolyze these compounds and yield a Xuorescent response [36, 37] . To illustrate this, we report data in the Supplementary material that prove that the previously described series of Xuorescent substrates for sEH [24] are excellent substrates for other EHs and esterases. Furthermore, similar products are excellent cytochrome P450 substrates [38, 39] . Thus, as a cautionary note, sEH activity tests of cells or cell lysates are not recommended with these compounds. This system as formatted requires at least partially puriWed enzyme and/or judicious use of enzyme inhibitors for proper performance.
Epoxide hydrolases, especially from microorganisms, are used for the production of chiral epoxides [40] . If used as a competitive substrate, the Xuorescent assay developed in this study could be easily employed to screen libraries of pure oxirane enantiomers and to determine the enantioselectivity of a particular enzyme.
The cyanohydrin rearrangement concept leading to the formation of a Xuorescent aldehyde used in this study for HsEH has also been used for esterases and P450 assay development (for more details about synthesis and assay optimization, see Refs. [36] [37] [38] [39] ). This concept can be extended to other Xuorescent aldehydes to shift excitation and emission maxima. Alternatively, the assay can be set up to yield an absorbance or luminescent signal.
Conclusion
In the current study, we have developed and validated a Xuorescent endpoint assay for the HTS of human soluble epoxide hydrolase inhibition. The option of employing ZnSO 4 at a Wnal concentration greater than 0.1 M as stop solution was provided. This test system will facilitate the HTS of large compound libraries with the objective to discover currently unknown potent sEH inhibitors leading to novel drugs for cardiovascular disease treatment.
